



Alexion Overview

Alexion is a global biopharmaceutical company that discovers, develops and delivers life-changing therapies for patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of the complement system, which regulates an important part of the body's immune response.

Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor approved for the treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. Soliris has been approved by the U.S. Food and Drug Administration (March 2007), the European Commission (June 2007), Health Canada (January 2009) and Australia's Therapeutic Goods Administration (February 2009). Soliris is commercially available in more than 30 countries. The company has submitted a marketing application for Soliris in Japan and is working toward seeking regulatory approval in other countries in Asia and South America.

Alexion was formed in 1992 and went public four years later (NASDAQ: ALXN). The company currently employs more than 500 people worldwide, and has its company headquarters in Cheshire, Connecticut. Additional facilities include a manufacturing plant in Smithfield, Rhode Island, primary European facilities in Paris, Brussels and Lausanne, Switzerland, with country offices in several major European nations. In 2009, the company also established offices in Tokyo and Sydney to support global expansion goals.

Ultra-Rare Diseases

Alexion is focused on providing treatments for ultra-rare and serious diseases, particularly those which profoundly affect a person's survival and quality of life, and for which there are few, if any, effective treatment options. Through the company's experience with Soliris and PNH, Alexion has developed exceptional scientific and commercial expertise in the field of ultra-rare diseases, generally defined as conditions that affect fewer than 20 people per one million of population.

The impact of rare disease on patients and their families can be profound. Many rare disorders are severe, chronic and progressive, and are marked by pain, disability and high mortality rates. The seriousness of rare diseases is often compounded by a lack of scientific knowledge, leading to missed diagnoses, mis-diagnoses and sub-optimal treatment. While there are many scientific, regulatory and commercial hurdles associated with the development of rare and ultra-

rare disease therapies, Alexion will continue exploring potential treatments for patients with other rare disorders – a commitment reflected in our research and development programs.

The Future of Alexion

Alexion's research and development efforts continue to build on the company's expertise in complement inhibition and antibody development, particularly in three main areas:

- Continuing support of the company's PNH programs to expand knowledge of the disease including its diagnosis, clinical consequences and optimal treatment, with the goal of reducing the complications and risks associated with the disease.
- Investigating Soliris as a potential treatment for patients with other life-threatening and often rare diseases in which complement activation plays a role and where current treatment options remain inadequate.
- Building Alexion's oncology program through the development of our anti-CD200 antibody as a treatment for patients with hematological malignancies and solid tumors.

For more information on Alexion please visit www.alexionpharm.com.